Weight Loss Jabs: Real-World Results May Vary
- weight loss medications, while promising, may not deliver the same dramatic results in everyday use as seen in clinical trials.
- Though,research presented at the American Society for Metabolic and Bariatric Surgery 2025 annual scientific meeting indicates that these GLP-1 RAs might not yield such significant weight loss in...
- The research team tracked 38,545 individuals prescribed semaglutide or tirzepatide and compared their progress to 12,540 patients who opted for bariatric surgery.
Real-world results of weight loss jabs may leave you wanting. A new study reveals these medications, like Wegovy and Mounjaro, might not deliver the same dramatic results as seen in clinical trials. Researchers found that while the primary_keyword shows promise initially, patients using these injectables—mimicking a key hormone—often experience less weight reduction compared to those undergoing bariatric surgery. The findings, presented at a recent medical conference, assessed over 51,000 patients. This News Directory 3 article details how cost and access issues may influence the secondary_keyword’s long-term effectiveness, offering insights into realistic expectations for obesity treatment. Discover what’s next …
Weight Loss Jabs: Real-World Results Lag Clinical Trial Expectations
Updated June 17, 2025
weight loss medications, while promising, may not deliver the same dramatic results in everyday use as seen in clinical trials. A recent study compared the effectiveness of weight loss jabs, such as Wegovy and Mounjaro, to bariatric surgery. The drugs, containing semaglutide and tirzepatide, have revolutionized obesity treatment, with initial studies suggesting up to 20% body weight loss after 72 weeks.
Though,research presented at the American Society for Metabolic and Bariatric Surgery 2025 annual scientific meeting indicates that these GLP-1 RAs might not yield such significant weight loss in real-world scenarios. The study, which has not yet been peer-reviewed, analyzed data from over 51,000 patients with a BMI of 35 or higher, all eligible for either weight loss surgery or medication.
The research team tracked 38,545 individuals prescribed semaglutide or tirzepatide and compared their progress to 12,540 patients who opted for bariatric surgery. The observation period extended up to three years. After adjusting for factors like age, BMI, and pre-existing health conditions, the study found that surgery consistently lead to greater weight loss than medication at all measured intervals.
as a notable example, two years post-procedure, bariatric surgery patients experienced an average 26.5% reduction in body weight, while those on GLP-1 RAs saw only a 5.7% decrease.
The moast reliable way to lose 20% to 30% of your weight is to get a bariatric operation.
Dr. Karan Chhabra, from New York University’s Grossman School of Medicine and the study’s senior author, noted the discrepancy.He suggested that cost and access barriers might hinder long-term medication use. He also pointed to the importance of proper dosage adjustments, side-effect monitoring, and comprehensive support from doctors.
Chhabra emphasized the need for further research to maximize the effectiveness of these medications.He stressed that patients should have realistic expectations based on real-world data when choosing a treatment for obesity.
Naveed Sattar, a professor at the University of Glasgow, highlighted previous trials showing substantial weight loss with tirzepatide over three years.However,he acknowledged that many patients discontinue medication due to cost or poorly managed side effects.Sattar added that bariatric surgery, when performed well, can be a cost-effective long-term solution, though patients often prefer medication initially.
What’s next
Further studies are needed to determine how to optimize the use of weight loss jabs and address barriers to access and adherence, ensuring patients receive the most effective treatment for obesity.